《大行報告》大摩對中資醫藥、研發、醫療設備、分銷及中藥股投資評級及目標價(表)
摩根士丹利發表研究報告,對中資醫藥、研發、醫療設備、分銷及中藥股投資評級及目標價表列如下:
股份?投資評級?目標價(港元)
首選股
恆端醫藥(600276.SH)?增持?72元人民幣
信達生物(01801.HK)?增持?95元
藥明生物(02269.HK)?增持?175元
創新藥/生物醫藥股
和譽-B(02256.HK)?增持?13.6元
康方生物-B(09926.HK)?增持?68.6元
康寧傑瑞製藥-B(09966.HK)?增持?31.2元
騰盛博藥-B(02137.HK)?增持?50.27->46元
石藥集團(01093.HK)?增持?12元
基石藥業-B(02616.HK)?增持?20.5->10.9元
北海康成-B(01228.HK)?增持?11元
雲頂新耀-B(01952.HK)?增持?96.2元
翰森製藥(03692.HK)?增持?38.7->33.6元
和鉑醫藥-B(02142.HK)?增持?13.9元
和黃醫藥(HCM.US)?增持?40.3->46.3美元
諾誠健華-B(09969.HK)?增持?35.3元
康諾亞-B(02162.HK)?增持?74.8元
李氏大藥廠(00950.HK)?增持->與大市同步?6->4.1元
歐康維視生物-B(01477.HK)?增持?33.5元
榮昌生物-B(09995.HK)?增持?134.1元
先聲藥業(02096.HK)?增持?11.5元
中生製藥(01177.HK)?增持?10元
三生製藥(01530.HK)?與大市同步?8.5元
歌禮制藥-B(01672.HK)?與大市同步->減持?2.8->2.6元
研發
藥明康德(02359.HK)?增持?211元
醫療設備
先瑞達醫療-B(06669.HK)?增持?25元
微創醫療(00853.HK)?增持?53元
沛嘉醫療-B(09996.HK)?增持?30元
威高股份(01066.HK)?與大市同步?17.3元
歸創通橋-B(02190.HK)?增持?58元
醫院股
海吉亞(06078.HK)?增持?90元
錦欣生殖(01951.HK)?增持?18->12.4元
華潤醫療(01515.HK)?與大市同步?7.55->5.5元
雍禾醫療(02279.HK)?增持?17元
線上保健股
阿裏健康(00241.HK)?增持?13元
平安好醫生(01833.HK)?與大市同步?43元
分銷商
上海醫藥(02607.HK)?增持?20.8元
國藥控股(01099.HK)?與大市同步?21元
華潤醫藥(03320.HK)?與大市同步?5.5元
製藥股
康哲藥業(00867.HK)?增持?22元
賽生藥業(06600.HK)?增持?18.8元
石四藥(02005.HK)?增持?6.5元
復星醫藥(02196.HK)?與大市同步?54元
東陽光藥(01558.HK)?與大市同步?7元
聯邦製藥(03933.HK)?與大市同步?6.8元
麗珠醫藥(01513.HK)?減持?22.6元
綠葉製藥(02186.HK)?減持?3.6元
原料藥股
海普瑞(09989.HK)?增持?14.2元
中藥股
同仁堂國藥(03613.HK)?增持?16.5元
中國中藥(00570.HK)?增持?6.3元
白雲山(00874.HK)?與大市同步?23.5元
神威藥業(02877.HK)?與大市同步?7.9元
同仁堂科技(01666.HK)?與大市同步?6.9元
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.